News & Updates

Capsular switching and emergence of vaccine escape variants after PCV introduction

01 Jul 2025

While pneumococcal conjugate vaccines (PCVs) have greatly reduced the global burden of pneumococcal disease, the emergence of disease caused by non-vaccine type (NVT) pneumococci, through serotype replacement and/or serotype (capsular) switching, remains a significant challenge. This article reviews the process of vaccine escape by capsular switching and the resulting impact on PCVs’ effectiveness.

Capsular switching and emergence of vaccine escape variants after PCV introduction

01 Jul 2025

Exploring alternative neoadjuvant chemotherapy options for the KEYNOTE-522 regimen: Insights from real-world experience within HK’s public healthcare system

27 Jun 2025 by

Despite positive outcomes with the KEYNOTE-522 regimen for triple-negative breast cancer (TNBC), its implementation faces challenges due to resource constraints in Hong Kong’s public healthcare system. Consultant Dr Thomas Kwan-Hang Lau and Resident Dr Kang Li of the Department of Clinical Oncology at Prince of Wales Hospital (PWH) shared insights and a case series on the use of Q3W and Q1W chemotherapy for the KEYNOTE-522 regimen in PWH and explored alternative neoadjuvant chemotherapy options.

Exploring alternative neoadjuvant chemotherapy options for the KEYNOTE-522 regimen: Insights from real-world experience within HK’s public healthcare system

27 Jun 2025

VIDEO: Real-world and clinical trial data on apalutamide in mHSPC

26 Jun 2025 by

Dr Darren Poon, Specialist in Clinical Oncology at Hong Kong Sanatorium & Hospital and Honorary Clinical Associate Professor at the Chinese University of Hong Kong, shares key insights from TITAN and OASIS studies and highlights the association between PSA response and survival outcomes.

VIDEO: Real-world and clinical trial data on apalutamide in mHSPC

26 Jun 2025

ESCMID Global 2025: Real-world effectiveness of PCV20 against IPD and ACP among older adults in the US

25 Jun 2025 by

At the 2025 Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global 2025), Ms Amanda Miles, Vaccines Real World Evidence Scientist of Pfizer Vaccines, New York, New York, US, presented the first real-world (RW) data showing the effectiveness of the 20-valent pneumococcal conjugate vaccine (PCV20) in preventing invasive pneumococcal disease (IPD) and all-cause pneumonia (ACP) among US adults aged ≥65 years.

ESCMID Global 2025: Real-world effectiveness of PCV20 against IPD and ACP among older adults in the US

25 Jun 2025

Once-monthly PCSK9 inhibitor in a patient with FH at very high CV risk

25 Jun 2025 by

A 62-year-old lady first presented on 15 September 2023 with severe chest pain typical of acute coronary syndrome (ACS), pointing to an imminent heart attack. She had been experiencing chest pain and shortness of breath on exertion over the past year, which had worsened in the 3 months prior to presentation, especially when she played tennis. She eventually had to quit all sports activities. The patient did not smoke or drink and had good past health, apart from some renal cysts. She had no history of atherosclerotic cardiovascular disease (ASCVD), but her younger sister suffered acute myocardial infarction (MI) at the age of 51 years, suggesting familial hypercholesterolaemia (FH).

Once-monthly PCSK9 inhibitor in a patient with FH at very high CV risk

25 Jun 2025

Expert insights on RSV vaccination: Protecting vulnerable high-risk older adults

25 Jun 2025 by

Respiratory syncytial virus (RSV) infection, especially in the elderly and older adults with one or more comorbidities, may lead to severe complications that require hospitalization, or even death. At the 2nd Hong Kong RSV Summit, Professor Ivan Hung of the Department of Medicine, University of Hong Kong, Hong Kong, and Professor Lucy Morgan of the University of Sydney and Macquarie University, Sydney, Australia, discussed efficacy and safety data of the recombinant adjuvanted RSVPreF3 vaccine and the importance of protecting the high-risk population ≥50 years of age against RSV infection and infection-associated risks.

Expert insights on RSV vaccination: Protecting vulnerable high-risk older adults

25 Jun 2025

$Use of an SGLT2i in a patient with heart failure with preserved ejection fraction$

Use of an SGLT2i in a patient with heart failure with preserved ejection fraction

25 Jun 2025 by

A 70-year-old male with a history of atrial fibrillation (AF), who was seen regularly at our Cardiology clinic, noted progressively worsening shortness of breath (SoB) and reduced exercise tolerance (New York Heart Association [NYHA] functional class II) over the past 6 months.

Use of an SGLT2i in a patient with heart failure with preserved ejection fraction

25 Jun 2025

A turning point in nAMD treatment with high-dose aflibercept formulation

24 Jun 2025 by

Increasing experience among ophthalmologists and patients attests to the durable efficacy and safety of the 8 mg formulation of the anti–vascular endothelial growth factor (anti-VEGF), aflibercept, in the treatment of neovascular age-related macular degeneration (nAMD). At an industrysponsored meeting, Dr Kenneth Fan of the Retina Consultants of Texas in Houston, Texas, US, reaffirmed the benefits of high-dose aflibercept in nAMD, highlighting how the positive experiences of his patients align with results of the pivotal PULSAR trial.

A turning point in nAMD treatment with high-dose aflibercept formulation

24 Jun 2025

AAD 2025: Key insights on abrocitinib in atopic dermatitis management

24 Jun 2025

Atopic dermatitis (AD) poses a significant disease burden, with effective symptom management remaining a challenge in diverse populations. This article highlights new data on abrocitinib, an oral Janus kinase 1 (JAK1) inhibitor, presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting, including its real-world effectiveness in Chinese patients, clinical findings on sleep improvement, and long-term safety in young adults

AAD 2025: Key insights on abrocitinib in atopic dermatitis management

24 Jun 2025

Dienogest in long-term management of endometriosis

24 Jun 2025 by

Characterized by high postpartum and postoperative recurrence rates, endometriosis requires continuous management. At a Bayer-sponsored symposium, Dr Yong-Wook Jung of Cha Gangnam Medical Center, South Korea, discussed the paradigm shift in the management of endometriosis, while Dr Pong-Mo Yuen, Director of Minimally Invasive Gynaecology at Hong Kong Sanatorium & Hospital, shared several patient cases illustrating long-term treatment with dienogest.

Dienogest in long-term management of endometriosis

24 Jun 2025

News & Updates

Filter by Specialty:

Specialty:

Capsular switching and emergence of vaccine escape variants after PCV introduction

Capsular switching and emergence of vaccine escape variants after PCV introduction

Exploring alternative neoadjuvant chemotherapy options for the KEYNOTE-522 regimen: Insights from real-world experience within HK’s public healthcare system

Exploring alternative neoadjuvant chemotherapy options for the KEYNOTE-522 regimen: Insights from real-world experience within HK’s public healthcare system

VIDEO: Real-world and clinical trial data on apalutamide in mHSPC

VIDEO: Real-world and clinical trial data on apalutamide in mHSPC

ESCMID Global 2025: Real-world effectiveness of PCV20 against IPD and ACP among older adults in the US

ESCMID Global 2025: Real-world effectiveness of PCV20 against IPD and ACP among older adults in the US

Once-monthly PCSK9 inhibitor in a patient with FH at very high CV risk

Once-monthly PCSK9 inhibitor in a patient with FH at very high CV risk

Expert insights on RSV vaccination: Protecting vulnerable high-risk older adults

Expert insights on RSV vaccination: Protecting vulnerable high-risk older adults

Use of an SGLT2i in a patient with heart failure with preserved ejection fraction

Use of an SGLT2i in a patient with heart failure with preserved ejection fraction

A turning point in nAMD treatment with high-dose aflibercept formulation

A turning point in nAMD treatment with high-dose aflibercept formulation

AAD 2025: Key insights on abrocitinib in atopic dermatitis management

AAD 2025: Key insights on abrocitinib in atopic dermatitis management

Dienogest in long-term management of endometriosis

Dienogest in long-term management of endometriosis